Agenus Inc (AGEN) stock
Close on Nov 17, 2026Market cap $279.58MP/E –Yield –
Agenus Inc grew revenue 30.5% to $132.69M over the twelve months to Jun 30, 2026. Free cash flow was -$98.50M. At the latest close the market valued the company at $279.58M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $279.58M
- P/E ratio
- –
- Price to sales
- 2.11
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -35.23%
Fundamentals
- Revenue
- $132.69M
- EPS, diluted
- $0.00
- Free cash flow
- -$98.50M
- Book value per share
- -$4.82
- Diluted shares
- 41M
Trading
- Next earnings
- Mar 15, 2027 (estimated, before the open)
- Previous close
- $6.29
- Open
- $6.19
- Day's range
- $5.96 – $6.45
- Volume
- 859,413
- Average volume (20 days)
- 685,142
- Index membership
- Russell 2000 (since Jun 2026)
- 52-week range
- $2.71 – $10.31
- RSI (14 days)
- 41.5
- Volatility (1 year)
- 120.6%
- Relative volume
- 0.18×
On 2 of our idea lists: Institutions accumulating, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | AGEN | S&P 500 | Difference | AGEN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +2.8% | -3.1% | +5.9 pts | ||
| 3 months | -13.1% | -4.0% | −9.1 pts | ||
| Year to date | +97.8% | +9.4% | +88.4 pts | ||
| 1 year | +43.8% | +12.4% | +31.4 pts | ||
| 3 years | -55.0% | +70.2% | −125.2 pts | -23.4% | +19.4% |
| 5 years | -91.0% | +69.0% | −160.0 pts | -38.3% | +11.1% |
| 10 years | -93.8% | +295.7% | −389.5 pts | -24.3% | +14.7% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Agenus filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Results
About Agenus
Biological Products, (No Diagnostic Substances)
Agenus Inc. operates as a commercial-stage and clinical biopharmaceutical company focused on clinical products, pre-commercial products, and clinical research services. The company provides specialized research and development manufacturing services, licenses proprietary intellectual property, and manages collaborative commercial agreements. Its primary operational activities encompass clinical product distribution, contract research, collaborative agreements, and named patient programs. Agenus engages with commercial customers and healthcare partners, including Incyte Corporation, Bristol Myers Squibb, Gilead Sciences, Betta Pharmaceuticals, and GlaxoSmithKline.
Company profile, executives and historyAgenus stock: common questions
What is Agenus's stock price?
AGEN closed at $6.21 on Nov 17, 2026, down 1.27% on the day. Over the past 52 weeks it traded between $2.71 and $10.31.
What is Agenus's market cap?
Agenus was worth $279.58M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is AGEN's P/E ratio?
Agenus lost money over fiscal 2025 (diluted EPS $0.00), so it has no meaningful P/E ratio.
How much revenue does Agenus make?
Agenus reported revenue of $132.69M for the twelve months to Jun 30, 2026, up 30.5% from a year earlier.
Does Agenus pay a dividend?
No. Agenus has not paid a cash dividend over the last twelve months.
When does Agenus report earnings next?
Agenus is expected to report Q4 FY2026 results on Mar 15, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has AGEN stock performed over the past year?
Including dividends, AGEN returned +43.8% over the past year, against +12.4% for the S&P 500.
How many AGEN shares are sold short?
8M shares were sold short at the latest FINRA report, 18.06% of the float, or 10.7 days of average trading volume.
Who are Agenus's competitors?
Companies most similar to Agenus by business, industry and size include BEAM, RGNX, DNA, AUTL, GLUE.
See a number that looks wrong?